Abstract
Background:Cancer immunotherapy with immune checkpoint inhibitors (ICI) may cause immune-related adverse events (irAEs). Glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs) are used for rheumatic irAEs treatment. Yet, high-dose GC may...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
